Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

NICE appraisal fees to be introduced despite opposition

NICE appraisal fees to be introduced despite opposition 14 Dec 2018
Concessions made for small companies. England’s cost effectiveness watchdog NICE is to start charging pharmaceutical companies for appraisals of their drugs from April 2019, despite considerable resistance from the industry ... The new charges are

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done 14 Dec 2018
Room for manoeuvre after initial rejection. NICE has issued draft guidance not recommending two new rival treatments for the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR) – Alnylam’s Onpattro and ... Gaining NICE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer 30 Nov 2018
But it is only available via the CDF for now. England's cost effectiveness watchdog NICE has recommended BMS' Opdivo  as an adjuvant treatment for skin cancer, reversing its initial decision ... NICE has said the drugmaker needs to compare Opdivo with

NICE lung cancer backing for Keytruda is biggest expansion yet

NICE lung cancer backing for Keytruda is biggest expansion yet 22 Nov 2018
NICE has, however, only given the green light to MSD's drug via the Cancer Drugs Fund (CDF), as there isn’t enough evidence yet for routine NHS use. ... benefits,” said Meindert Boysen, director of the NICE Centre for Health Technology Evaluation.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs 30 Oct 2018
Both companies made same error in modelling, says NICE. NICE has rejected rival treatments for high levels of potassium in the blood, known as hyperkalaemia, AZ’s Lokelma and Vifor’s ... AZ will be hoping its greater marketing muscle will help it

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Infographics